Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.

Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature. Skin Therapy Lett. 2016 Mar;21(2):1-5 Authors: Blakely K, Gooderham M, Papp K Abstract Atopic dermatitis results when aberrant barrier function and immune activation occur within the skin. Standard therapies for atopic dermatitis have fallen short, prompting efforts to discover novel therapeutics for this disease. Of these, dupilumab, a fully human monoclonal antibody that inhibits the actions of both IL-4 and IL-13, has shown the greatest promise. Clinical trials of systemic dupilumab in moderate-to-severe atopic dermatitis have demonstrated marked improvement in patient symptoms, including pruritus and clinically visible disease. Importantly, dupilumab treatment has been correlated with changes in the molecular signature of diseased skin, with reduction of both inflammatory and proliferative markers. Dupilumab recently received US FDA breakthrough therapy designation for atopic dermatitis, with ongoing trials in both adult and pediatric populations. Altogether, dupilumab has shed new light on the pathomechanisms driving atopic dermatitis and is making unprecedented advances towards highly effective control of this debilitating disease. PMID: 27223113 [PubMed - in process]
Source: Skin Therapy Letter - Category: Dermatology Authors: Tags: Skin Therapy Lett Source Type: research

Related Links:

We report a case of a 55-year-old African American woman who developed intensely pruritic papules and plaques on bilateral hands. Histological examination demonstrated acute spongiotic dermatitis with lymphocyte exocytosis into the epidermis. Taken together, a diagnosis of lichen planus–like atopic dermatitis was made. This case serves to highlight that lichen planus–like atopic dermatitis can develop on hands and that it presents as spongiotic dermatitis with lymphocyte exocytosis into the epidermis. Correlating the clinical presentation with histopathological findings will assist in establishing the diagnosis...
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Extraordinary Case Report Source Type: research
Publication date: Available online 19 February 2020Source: The LancetAuthor(s): Kirsten P Perrett, Rachel L Peters
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: Available online 19 February 2020Source: The LancetAuthor(s): Håvard Ove Skjerven, Eva Maria Rehbinder, Riyas Vettukattil, Marissa LeBlanc, Berit Granum, Guttorm Haugen, Gunilla Hedlin, Linn Landrø, Benjamin J Marsland, Knut Rudi, Kathrine Dønvold Sjøborg, Cilla Söderhäll, Anne Cathrine Staff, Kai-Håkon Carlsen, Anna Asarnoj, Karen Eline Stensby Bains, Oda C Lødrup Carlsen, Kim M Advocaat Endre, Peder Annæus Granlund, Johanne Uthus HermansenSummaryBackgroundSkin emollients applied during early infancy could prevent atopic dermatitis, and early comple...
Source: The Lancet - Category: General Medicine Source Type: research
Authors: Ingawale DK, Mandlik SK Abstract Inflammation is a physiological intrinsic host response to injury meant for removal of noxious stimuli and maintenance of homeostasis. It is a defensive body mechanism that involves immune cells, blood vessels and molecular mediators of inflammation. Glucocorticoids (GCs) are steroidal hormones responsible for regulation of homeostatic and metabolic functions of body. Synthetic GCs are the most useful anti-inflammatory drugs used for the treatment of chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), allergies, multiple sclerosis, te...
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
INDIANAPOLIS, Feb. 20, 2020 -- (Healthcare Sales &Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Dermira, Inc. (NASDAQ: DERM). The acquisition expands Lilly's immunology pipeline wi... Biopharmaceuticals, Dermatology, Mergers &Acquisitions Eli Lilly, Dermira, lebrikizumab, atopic dermatitis, QBREXZA, glycopyrronium
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Publication date: Available online 19 February 2020Source: Research in Veterinary ScienceAuthor(s): J.S. Yoon, K. Nishifuji, T. IwasakiAbstractCeramides (CERs) in the stratum corneum (SC) are known to play a crucial role in determining skin barrier function in dogs. We aimed to develop an in vitro culture system that synthesized epidermal CER classes to better understand the synthesis of CER classes in canine SC.. Canine keratinocyte cells (MSCEK) at appropriate confluency were incubated with high Ca2+ (1.8 mM CaCl2) supplemented serum-free medium. Eight days post Ca2+ application, the surface of cultured MSCEK was broad...
Source: Research in Veterinary Science - Category: Veterinary Research Source Type: research
ConclusionAn increase of IL6 and IL12 in cAC was found in the studied population. These two cytokines may be potential immunotherapy targets cAC classification.
Source: Research in Veterinary Science - Category: Veterinary Research Source Type: research
Publication date: Available online 24 January 2020Source: Journal of Genetics and GenomicsAuthor(s): Qianru Huang, Xu Liu, Yujia Zhang, Jingyao Huang, Dan Li, Bin LiAbstractRegulatory T (Treg) cells, a subtype of immunosuppressive CD4+ T cells, are vital for maintaining immune homeostasis in healthy people. Forkhead box protein P3 (FOXP3), a member of the forkhead–winged-helix family, is the pivotal transcriptional factor of Treg cells. The expression, post-translational modifications, and protein complex of FOXP3 present a great impact on the functional stability and immune plasticity of Treg cells in vivo. In ...
Source: Journal of Genetics and Genomics - Category: Genetics & Stem Cells Source Type: research
Loss of epidermal microRNA, miR-335, causes skin barrier defects in atopic dermatitis. Belinostat, a histone deacetylase inhibitor, restores miR-335 expression and represents a potential therapeutic for treatment of atopic dermatitis.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
Conclusions: Ultraviolet-A1 phototherapy appears to be efficacious for the treatment of hand and foot eczema as well as atopic dermatitis. However, in patients with scleroderma, the response was partial and needed a longer duration of treatment.
Source: Indian Journal of Dermatology, Venereology and Leprology - Category: Dermatology Authors: Source Type: research
More News: Clinical Trials | Dermatitis | Dermatology | Pediatrics | Skin